Literature DB >> 26256288

Extended follow-up of pediatric liver transplantation patients receiving once daily calcineurin inhibitor.

Henry C Lin1, Hector Melin-Aldana2, Saeed Mohammad3, Udeme D Ekong4, Estella M Alonso3.   

Abstract

We describe longitudinal results in a cohort of pediatric liver transplant patients successfully minimized to once daily CNI monotherapy for longer than five yr and assess changes in liver biochemistries and liver histology. A retrospective chart review of all pediatric liver transplant patients at a single center was performed. Biopsies and serum biochemistries (AST, ALT, total bilirubin, direct bilirubin, INR, creatinine) are reported at time points: PM, five-yr, seven-yr, and nine-yr post-minimization. Biopsies were assessed for inflammation and fibrosis using Ishak and Batts grading systems. Successful minimization to daily CNI monotherapy was defined as normal liver enzymes with no episodes of rejection. Thirty-three patients have successfully remained on once daily CNI for >5 yr, and 19/33 of these patients have serial liver biopsies available for review. We report on the clinical and histological findings of these 19 patients. All 19 patients continue to have normal liver biochemistries. On post-minimization biopsies, fibrosis progressed by ≥2 stages in one patient (5.3%) despite normal liver biochemistries. Carefully selected patients can tolerate minimization to once daily CNI monotherapy as few have progression of fibrosis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  calcineurin inhibitors; immunosuppression minimization; liver transplant; pediatric transplantation

Mesh:

Substances:

Year:  2015        PMID: 26256288     DOI: 10.1111/petr.12557

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Prediabetes in Pediatric Recipients of Liver Transplant: Mechanism and Risk Factors.

Authors:  Emily R Perito; Robert H Lustig; Philip Rosenthal
Journal:  J Pediatr       Date:  2016-12-29       Impact factor: 4.406

2.  Center variation in screening for and management of metabolic syndrome in pediatric liver transplant recipients: A survey of SPLIT centers.

Authors:  Kelly Hilk; Melissa Zerofsky; Sue Rhee; Philip Rosenthal; Emily R Perito
Journal:  Pediatr Transplant       Date:  2019-01-21

3.  Improvements in Disease-Specific Health-Related Quality of Life of Pediatric Liver Transplant Recipients During Immunosuppression Withdrawal.

Authors:  Saeed Mohammad; Shikha S Sundaram; Kristen Mason; Steven Lobritto; Mercedes Martinez; Yumirle P Turmelle; John Bucuvalas; Sandy Feng; Estella M Alonso
Journal:  Liver Transpl       Date:  2021-05       Impact factor: 5.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.